Evaxion A/S reports results for the quarter ended June 30 - Earnings Summary
Evaxion A/S reports results for the quarter ended June 30 - Earnings Summary
Evaxion A/S EVAX.OQ reported a quarterly adjusted loss of 50 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.00. The mean expectation of three analysts for the quarter was for a loss of 31 cents per share. Wall Street expected results to range from -47 cents to -1 cents per share.
Reported revenue was zero; analysts expected zero.
Evaxion A/S's reported EPS for the quarter was a loss of 50 cents.
The company reported a quarterly loss of $3.73 million.
Evaxion A/S shares had risen by 1.6% this quarter and lost 34.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Evaxion A/S is $10.00, about 68.5% above its last closing price of $3.15
This summary was machine generated from LSEG data August 20 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.31 | -0.50 | Missed |
Mar. 31 2026 | -0.30 | -0.50 | Missed |
Dec. 31 2025 | -0.30 | -1.00 | Missed |
Sep. 30 2025 | 0.40 | 0.50 | Beat |
Recent news on Evaxion A/S
See all newsEvaxion A/S reports results for the quarter ended June 30 - Earnings Summary
Denmark's Evaxion Q2 net loss narrows on lower expenses
Brief: Evaxion Q2 Basic EPS USD -0.01
Evaxion A/S expected to post a loss of 31 cents a share - Earnings Preview
Brief: Evaxion A/S - Expands Pipeline Of Cancer Vaccine Programs With Evx-05 Against Brain Cancer Glioblastoma